Arkolith/Insider Trading/TERN/Form 4

Burroughs Amy L.

Chief Executive Officer, DirectorTerns Pharmaceuticals, Inc. (TERN) · full profile →Form 4 · filed Jan 16, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.5M
Net Open-Market Flow
-$2.5M
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 15, 2026Sell(S)8K$37.53$282K289K
Jan 15, 2026Option exercise(M)27K$4.64$126K316K
Jan 15, 2026Option exercise(M)27K$4.64$126K343K
Jan 15, 2026Option exercise(M)15K$4.64$68K358K
Jan 15, 2026Sell(S)61K$37.02$2.3M296K
Jan 14, 2026Grant(A)150K—$0289K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 15, 2026Option exercise(M)15K—$0985K
Jan 15, 2026Option exercise(M)27K—$0999K
Jan 15, 2026Option exercise(M)27K—$01.0M
Jan 14, 2026Grant(A)300K—$0300K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001872564-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML